Search Results

Featured Stories

Toggle

Showing 10 of 44 results

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

TEL AVIV, Israel & REYKJAVIK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates.

Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection

HERZUMA is a biosimilar to HERCEPTIN ®1 (trastuzumab) Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co.,...

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar

TRUXIMA Available Week of November 11 Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX KRX:068270) and Celltrion...

Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not

FOCUS study met all primary and secondary endpoints in both the quarterly and monthly dosing regimens in patients with chronic and episodic migraine Teva Pharmaceutical Industries Ltd. (NYSE and...

Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for

Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA ® (trastuzumab-pkrb)...

Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Thre

TRUXIMA ® is the first rituximab biosimilar to be approved in the United States Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the...

Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA f

If approved, CT-P10, a proposed biosimilar to Rituxan ® (rituximab), will be the first rituximab biosimilar to be approved in the United States Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical...

ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and On

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY TM (fremanezumab-vfrm) injection for the preventive...

Teva Appoints John Nason President, TAPI and Biologics Operations

Teva announced the appointment of John Nason to President, Teva Active Pharmaceutical Ingredients (TAPI), a role in which he leads the company’s vertically integrated business unit responsible for...

Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved GRANIX ® (tbo-filgrastim) Injection for a new vial presentati...